Log in

OTCMKTS:HEMAHemaCare Stock Price, Forecast & News

0.00 (0.00 %)
(As of 01/3/2020)
Today's Range
Now: $25.31
50-Day Range
MA: $25.31
52-Week Range
Now: $25.31
Volume5,500 shs
Average Volume59,577 shs
Market Capitalization$346.49 million
P/E RatioN/A
Dividend YieldN/A
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, and cord blood; and a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company's network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Current SymbolOTCMKTS:HEMA



Sales & Book Value

Annual SalesN/A



Market Cap$346.49 million
Next Earnings DateN/A
OptionableNot Optionable
0.00 (0.00 %)
(As of 01/3/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive HEMA News and Ratings via Email

Sign-up to receive the latest news and ratings for HEMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

HemaCare (OTCMKTS:HEMA) Frequently Asked Questions

How has HemaCare's stock been impacted by Coronavirus (COVID-19)?

HemaCare's stock was trading at $25.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HEMA shares have increased by 0.0% and is now trading at $25.31.
View which stocks have been most impacted by COVID-19

Has HemaCare been receiving favorable news coverage?

News stories about HEMA stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. HemaCare earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about HemaCare

Are investors shorting HemaCare?

HemaCare saw a drop in short interest in December. As of December 31st, there was short interest totaling 300 shares, a drop of 76.9% from the December 15th total of 1,300 shares. Based on an average trading volume of 180,800 shares, the short-interest ratio is currently 0.0 days.
View HemaCare's Short Interest

Who are some of HemaCare's key competitors?

What other stocks do shareholders of HemaCare own?

Who are HemaCare's key executives?

HemaCare's management team includes the following people:
  • Mr. Peter C. van der Wal, Pres, CEO & Director (Age 62)
  • Ms. Rochelle J. Martel M.B.A., CPA, Chief Financial Officer
  • Ms. Maria Pia Muniz, Sr. VP of Operations
  • Mr. Lou Juliano, Sr. VP of Global Sales & Bus. Devel.
  • Dr. Dominic Clarke, Global Head of Cell Therapy

What is HemaCare's stock symbol?

HemaCare trades on the OTCMKTS under the ticker symbol "HEMA."

How do I buy shares of HemaCare?

Shares of HEMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is HemaCare's stock price today?

One share of HEMA stock can currently be purchased for approximately $25.31.

How big of a company is HemaCare?

HemaCare has a market capitalization of $346.49 million.

What is HemaCare's official website?

The official website for HemaCare is www.hemagen.com.

How can I contact HemaCare?

HemaCare's mailing address is 15350 SHERMAN WAY SUITE 350, VAN NUYS CA, 91406. The company can be reached via phone at 818-226-1968 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.